Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/FJC.0000000000001619 | DOI Listing |
Radiol Case Rep
March 2025
Neuroradiology department, Hospital of specialities, Ibn Sina university hospital center, Rabat, Morocco.
Bilateral vertebral artery dissections account for only 8% of all vertebral artery dissections and cause just 2% of all ischemic strokes. They can occur spontaneously, even without any triggering factor. Classical clinical findings, such as headache or neck pain, may be absent, particularly in the context of a stroke.
View Article and Find Full Text PDFKidney Int Rep
January 2025
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Introduction: Factor XI/XIa (FXI/XIa) has emerged as a potential target for antithrombotic therapy, driven by preclinical evidence showing the role of FXI/XIa inhibition for preventing thrombosis without impeding hemostasis. This is particularly promising for patients at high risk of both thromboembolic events and bleeding, such as patients with end-stage kidney disease (ESKD) on hemodialysis (HD).
Methods: We systematically searched Embase, MEDLINE, and ClinicalTrials.
Cardiovasc Revasc Med
January 2025
Department of Cardiology, Ospedale dell'Angelo, AULSS3 Serenissima, Mestre, Venezia, Italy.
Background: Antithrombotic therapy (AT) after left atrial appendage occlusion (LAAO) in patients with non-valvular atrial fibrillation (NVAF) has the purpose of preventing device related thrombosis (DRT), avoiding embolic events; nevertheless, the correct antithrombotic regimen after LAAO is still under debate.
Aims: Aim of this substudy of the observational LOGIC registry was to describe the efficacy and safety of a light antithrombotic regimen, comprising single antiplatelet therapy or none, compared to a standard antithrombotic regimen, after a successful LAAO.
Methods: Patients with NVAF that underwent LAAO were previously included in the LOGIC registry.
J Am Med Dir Assoc
January 2025
EPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France; Université de Versailles Saint-Quentin-en-Yvelines, France.
Objective: We aimed to describe the medications prescribed to people aged ≥90 years.
Design: A cohort study was performed using data from the year 2022.
Setting And Participants: Using data from the French National Health Data System, people aged ≥90 years affiliated with the general insurance scheme were included.
Semin Thromb Hemost
January 2025
Department of Pediatric Gastroenterology, University of South Florida Morsani College of Medicine, Tampa, Florida.
The purpose of this study is to (1) estimate and compare the prevalence of venous thromboembolism (VTE) in children (age 0 to ≤21) with versus without cystic fibrosis (CF); (2) investigate putative associations between specific gastrointestinal (GI) manifestations and the development of VTE among children with CF. This was a multicenter case-control analysis among patients aged 0 to ≤ 21 years between 2010 and 2020, using the TriNetX Research Network. Data queries included ICD-9/10 (International Classification of Diseases-9th/10th Revision) diagnosis codes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!